Trials / Completed
CompletedNCT02411591
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination With Abemaciclib in Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is medical research evaluating the safety and efficacy of two new medicines (necitumumab and abemaciclib), administered in combination in participants affected by a defined type of advanced lung cancer (stage IV non-small-cell lung cancer).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Necitumumab | Administered IV. |
| DRUG | Abemaciclib | Administered orally. |
Timeline
- Start date
- 2015-06-04
- Primary completion
- 2017-06-23
- Completion
- 2019-05-28
- First posted
- 2015-04-08
- Last updated
- 2020-07-09
- Results posted
- 2020-07-09
Locations
15 sites across 3 countries: Belgium, France, Spain
Source: ClinicalTrials.gov record NCT02411591. Inclusion in this directory is not an endorsement.